Silexion Therapeutics Corp filed a Current Report on Form 8-K to announce the retroactive adjustment of its audited financial statements for the year ended December 31, 2025, and unaudited interim financial statements for the quarter ended March 31, 2026. These adjustments reflect a 1-for-10 reverse share split that was effected on May 28, 2026, following shareholder approval at an extraordinary general meeting held in April and May 2026. The adjusted financial statements are attached as Exhibit 99.1 and incorporated by reference into the filing. Silexion Therapeutics Corp operates in the biotechnology industry, developing RNA interference therapies for KRAS-driven cancers.
